Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Smoking Cessation
NCT07602699Phase 2Recruiting
- Sponsor
- University of Southern California
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: 7-day point prevalence abstinence at 27 weeks. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT07602699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602699.